Immuno-Oncology Startup Snatches $67m In Series A
This article was originally published in Scrip
Executive Summary
NextCure, a newly formed immuno-oncology company being led by Michael Richman, the former CEO of AstraZeneca plc-acquired biotech Amplimmune, has raised $67m in a series A financing round.
You may also be interested in...
NextCure Hopes Its Novel Target Therapies Will Treat Patients Not Helped By PD-1/L1 Inhibition
Emerging Company Profile: Based on discovery research at Yale, NextCure hopes S15 and other novel targets will provide new inroads in immuno-oncology, while much of the field remains focused on PD-1 inhibitors and combinations.
Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services
Scrip spoke with Managing Director Julie Sunderland about Biomatics' new $300m fund. Also, Silicon Valley Bank reveals its surprising Leerink buy, Perceptive Advisors raises $675m, Roivant brings in another $200m, and cell and gene therapy financings surge in the third quarter.
Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.